Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (91-100 of 342) with videos related to

Pageof 35
Sort By:
Clinical Trials (London, England)|August 25, 2021
Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scoresSarah M Weinstein, Laura C Coates, Philip S Helliwell, et al.
Clinical and Experimental Rheumatology|November 29, 2023
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestationsXenofon Baraliakos, Effie Pournara, Laura C Coates, et al.
Clinical Rheumatology|December 17, 2016
An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areasLaura C Coates, Laura Savage, Robin Waxman, et al.
Rheumatology (Oxford, England)|December 6, 2018
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumabLaura C Coates, Proton Rahman, Eliofotisti Psaradellis, et al.
Rheumatology (Oxford, England)|January 5, 2019
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activityRobert Landewé, Christopher T Ritchlin, Daniel Aletaha, et al.
The Journal of Rheumatology. Supplement|June 3, 2018
The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis DatabaseDafna D Gladman, Laura C Coates, Deepak R Jadon, et al.
The Lancet. Rheumatology|January 26, 2026
The path to interception in psoriatic disease: from conceptual clarity to clinical translationDylan McGagh, Ashley Elliott, Teresa Grohmann, et al.
Advances in Therapy|May 29, 2025
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative ReviewLinda Stein Gold, Kilian Eyerich, Joseph F Merola, et al.
RMD Open|December 13, 2024
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trialIain B McInnes, Philipp Sewerin, Mohamed Sharaf, et al.
Rheumatology and Therapy|April 12, 2022
Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World EvidenceLaura C Coates, Maarten de Wit, Amy Buchanan-Hughes, et al.
Pageof 35

Showing results (91-100 of 342) with videos related to

Sort By:
Pageof 35
Clinical Trials (London, England)|August 25, 2021
Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scoresSarah M Weinstein, Laura C Coates, Philip S Helliwell, et al.
Clinical and Experimental Rheumatology|November 29, 2023
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestationsXenofon Baraliakos, Effie Pournara, Laura C Coates, et al.
Clinical Rheumatology|December 17, 2016
An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areasLaura C Coates, Laura Savage, Robin Waxman, et al.
Rheumatology (Oxford, England)|December 6, 2018
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumabLaura C Coates, Proton Rahman, Eliofotisti Psaradellis, et al.
Rheumatology (Oxford, England)|January 5, 2019
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activityRobert Landewé, Christopher T Ritchlin, Daniel Aletaha, et al.
The Journal of Rheumatology. Supplement|June 3, 2018
The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis DatabaseDafna D Gladman, Laura C Coates, Deepak R Jadon, et al.
The Lancet. Rheumatology|January 26, 2026
The path to interception in psoriatic disease: from conceptual clarity to clinical translationDylan McGagh, Ashley Elliott, Teresa Grohmann, et al.
Advances in Therapy|May 29, 2025
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative ReviewLinda Stein Gold, Kilian Eyerich, Joseph F Merola, et al.
RMD Open|December 13, 2024
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trialIain B McInnes, Philipp Sewerin, Mohamed Sharaf, et al.
Rheumatology and Therapy|April 12, 2022
Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World EvidenceLaura C Coates, Maarten de Wit, Amy Buchanan-Hughes, et al.
Pageof 35